Check 35,000+ stocks against 26 valuation models and 37 quality factors

Huakang Biomedical Holdings Co Ltd (8622) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of Huakang Biomedical Holdings Co Ltd HK$0.09, price HK$0.16, upside -43.8%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · HK · ISIN KYG4644W1069

HB Thin data Sep 27, 2026

Huakang Biomedical Holdings Co Ltd

8622 · HK

Weakest SetupStrongly overvalued and low quality.

!Fair value HK$0.0900 · Strongly overvalued (−43.8%)

!Quality 38/100

!Expensive Growth (revenue 5y +5.2 %/yr)

!Loss-making · -17.7% net margin (TTM)

!Low debt · negative free cash flow

!Mixed vs. peers (4/10)

!Narrow moat 0/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear HK$0.0600 to bull HK$0.1200 Growth analysisrevenue history, year by year Quality 38/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Huakang Biomedical Holdings Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range HK$0.0850 – HK$0.7000 · fair‑value band HK$0.0600 – HK$0.1200 · the HK$0.1600 price screens above the HK$0.0900 fair value. Dashed = 300-day average. As of Sep 27, 2026.

Follow Huakang Biomedical Holdings Co in your weekly email

Every Wednesday you see whether Huakang Biomedical Holdings Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Joyzyme Group Limited, an investment holding company, engages in the research, production, and sale of male fertility in-vitro diagnostic (IVD) reagents in the People's Republic of China.

Joyzyme Group Limited, an investment holding company, engages in the research, production, and sale of male fertility in-vitro diagnostic (IVD) reagents in the People's Republic of China. The company provides biological reagents, including male fertility IVD reagents, parasite antibody detection reagents, and Epstein-Barr virus antibody detection reagent; healthcare products and supplements; and auxiliary reproductive supplies and equipment. The company sells its products directly to hospitals and medical institutions, as well as to distributors. The company was formerly known as Huakang Biomedical Holdings Company Limited and changed its name to Joyzyme Group Limited in January 2026. Joyzyme Group Limited was founded in 1992 and is based in Tsim Sha Tsui, Hong Kong.

Stock analysis

Huakang Biomedical Holdings Co Ltd (8622) currently trades at HK$0.1600, while our model-based Fair Value estimate is HK$0.0900, 43.8% below the price, so the stock looks overvalued today.

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: HK$0.0600 (bear) to HK$0.1200 (bull), the price of HK$0.1600 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Huakang Biomedical Holdings Co Ltd reported revenue of 28.3M CNY in FY2025 versus 26.1M CNY in FY2021, a compound +2.0%/yr. Reported net income was −5.0M CNY in FY2025.

Key figures

Market cap HK$103M (≈ $13.1M) · P/S ratio 3.65 · Net margin −17.7% · Return on equity −9.5% · Return on assets (EBIT) −9.0% · Operating margin −34.5% · Revenue (TTM) 28.3M CNY · Revenue growth (YoY) +18.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 77% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −44%, 8622 screens richer than that median.

Fair Value models

Bear HK$0.0600 Fair Value HK$0.0900 Bull HK$0.1200

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

NCAV (Graham) HK$0.0600 HK$0.0800 HK$0.1200 54

All 1 models by family

Asset-Based

NCAV (Graham) HK$0.0600 HK$0.0800 HK$0.1200 54

Open the full fair value analysis →

Notify me when 8622 reaches fair value

Put 8622 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 38/100

Of which business quality 41 · Market factors (momentum, volatility) 16

Profitability 15

Margins and returns on capital today

Quality Growth 33

Are margins and returns improving?

Cashflow 0

Earnings quality: real cash, not paper profit

Fin. Strength 99

Balance sheet, leverage, solvency risk

Investment 96

Disciplined investing over empire-building

Low Volatility 42

Calm price path (market factor)

Momentum 8

Price trend over the last 3–12 months (market factor)

52W Momentum 0

Distance to the 52-week high (market factor)

Net Issuance 22

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 23/100

The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Revenue growth 1 year

+11.5%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+3.7%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+5.2%

Start year 2020 (pandemic). Over 10 years: +3.8% a year

Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+3.8%

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−39.3% (2020) → −27.6% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

8622 screens overvalued: fair value 44% below the price. Compare with Merck KGaA →

Compare Huakang Biomedical Holdings Co Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 620 stocks

Beats the industry median on 3/8 measures

Overall it trails its industry peers.

Valuation

Quality Score 42 · Below median

Fair Value upside −43.8% · Below median

Profitability

Return on assets −7.5% · Bottom 25%

Net margin (TTM) −17.7% · Bottom 25%

Operating margin (TTM) −34.5% · Bottom 25%

Growth and dividend

Revenue growth 18.7% · Top 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.26× · Cheapest 25%

P/S (TTM) 0.47× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 16

FUTURE (revenue growth)94 · sector 20

PAST (return on equity)0 · sector 26

HEALTH (low debt)100 · sector 96

DIVIDEND (yield)0 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Merck KGaA MRK	€134.45	€108.94	−19%
Takeda Pharmaceutical Company TAK	$18.90	$11.45	−39%
Teva Pharmaceutical Industries Limited TEVA	$39.19	$20.88	−47%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,852	₹1,979	+7%
Galderma Group GALD	CHF 163.00	CHF 110.32	−32%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥44.86	¥49.35	+10%
Haleon plc HLN	$9.26	$8.49	−8%
Sandoz Group SDZ	CHF 71.16	CHF 40.32	−43%
Zoetis Inc ZTS	$70.30	$110.50	+57%
Divi's Laboratories Limited DIVISLAB	₹9,620	₹1,871	−81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Huakang Biomedical Holdings Co Ltd · Fair Value
HK$0.0900 −44%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/8622" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Huakang Biomedical Holdings Co Ltd · Fair Value</span><br><b style="font-size:20px">HK$0.0900</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−44%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Huakang Biomedical Holdings Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/8622

Frequently asked questions

Is Huakang Biomedical Holdings Co Ltd (8622) overvalued or undervalued?

As of Sep 27, 2026, our model estimates a fair value of HK$0.0900 versus a price of HK$0.1600, about −44% upside (overvalued).

What is the fair value of 8622?

Our model-based fair value for Huakang Biomedical Holdings Co Ltd is HK$0.0900 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$0.1600.

What is the quality score of 8622?

Huakang Biomedical Holdings Co Ltd has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Huakang Biomedical Holdings Co Ltd (8622)?

Our model-based price target is the fair value of HK$0.0900 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario HK$0.0600, optimistic scenario HK$0.1200. It is a calculation from audited fundamentals, not an analyst target.

What is the Huakang Biomedical Holdings Co Ltd stock forecast for 2026?

Our models put fair value at HK$0.0900, about −44% upside versus a price of HK$0.1600 (overvalued). Cautious scenario HK$0.0600, optimistic scenario HK$0.1200. The calculation is refreshed regularly with new filings.

What is the revenue of Huakang Biomedical Holdings Co Ltd (8622)?

Huakang Biomedical Holdings Co Ltd reported trailing-twelve-month revenue of about 28.3M CNY (latest available figure, as of Sep 27, 2026).

What is the intrinsic value of Huakang Biomedical Holdings Co Ltd (8622)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Huakang Biomedical Holdings Co Ltd it is HK$0.0900 per share (as of Sep 27, 2026), against a price of HK$0.1600. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).

Is Huakang Biomedical Holdings Co Ltd stock overvalued or undervalued in 2026?

As of Sep 27, 2026, 8622 trades above its calculated fair value: price HK$0.1600, fair value HK$0.0900, a gap of about −44% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 8622?

No. The price is what the market pays today (HK$0.1600); the fair value is what the company's own numbers justify (HK$0.0900). For Huakang Biomedical Holdings Co Ltd the two are HK$0.0700 per share apart. That gap is exactly why we show both numbers side by side.

How much is Huakang Biomedical Holdings Co Ltd worth?

The market values Huakang Biomedical Holdings Co Ltd at about HK$103M (market capitalisation, as of Sep 27, 2026). Per share that is HK$0.1600; our models calculate a fair value of HK$0.0900 per share.

What do the bullish and bearish scenarios say about 8622?

Our models span a range for Huakang Biomedical Holdings Co Ltd: cautious scenario HK$0.0600, base HK$0.0900, optimistic HK$0.1200 per share (as of Sep 27, 2026, price HK$0.1600). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Huakang Biomedical Holdings Co Ltd (8622)?

Balance-sheet figures for Huakang Biomedical Holdings Co Ltd (as of Sep 27, 2026): return on equity −9.5%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.

How far is 8622 from its 52-week high?

Huakang Biomedical Holdings Co Ltd trades at HK$0.1600, about 77% below its 52-week high of HK$0.7000 and 1% above the low of HK$0.1590 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.0900 is for.

Which stocks are comparable to Huakang Biomedical Holdings Co Ltd?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Huakang Biomedical Holdings Co Ltd stock attractive at the current price?

The data as of Sep 27, 2026: price HK$0.1600, calculated fair value HK$0.0900 (−44%), Quality Score 38/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 8622 calculated?

We run Huakang Biomedical Holdings Co Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.0900, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Huakang Biomedical Holdings Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Huakang Biomedical Holdings Co Ltd (8622)?

The closing price on Sep 30, 2026 was HK$0.1600. Our model-based fair value is HK$0.0900, about −44% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Huakang Biomedical Holdings Co Ltd right now?

The price sits above even our optimistic bull case (HK$0.1200). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$0.0600 to HK$0.1200) leaves room in how you read the outcome.

Key figures of Huakang Biomedical Holdings Co Ltd

How large is the market capitalisation of Huakang Biomedical Holdings Co Ltd (8622)?

The market capitalisation of Huakang Biomedical Holdings Co Ltd is HK$103M (≈ $13.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Huakang Biomedical Holdings Co Ltd (8622)?

The price-to-sales ratio of Huakang Biomedical Holdings Co Ltd is 3.65 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What is the net margin of Huakang Biomedical Holdings Co Ltd (8622)?

The net margin of Huakang Biomedical Holdings Co Ltd is −17.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Huakang Biomedical Holdings Co Ltd (8622)?

The return on equity (ROE) of Huakang Biomedical Holdings Co Ltd is −9.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Huakang Biomedical Holdings Co Ltd (8622)?

On an EBIT basis the return on assets of Huakang Biomedical Holdings Co Ltd is −9.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Huakang Biomedical Holdings Co Ltd (8622)?

The operating margin of Huakang Biomedical Holdings Co Ltd is −34.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Huakang Biomedical Holdings Co Ltd (8622)?

Revenue at Huakang Biomedical Holdings Co Ltd is growing +18.7% versus a year earlier (3y avg +3.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Huakang Biomedical Holdings Co Ltd (8622)?

Earnings per share at Huakang Biomedical Holdings Co Ltd are growing −41.4% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does Huakang Biomedical Holdings Co Ltd (8622) generate?

The free cash flow of Huakang Biomedical Holdings Co Ltd is −3.3M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net cash does Huakang Biomedical Holdings Co Ltd (8622) hold?

Huakang Biomedical Holdings Co Ltd holds more cash than debt, 32.0M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Huakang Biomedical Holdings Co Ltd in the live analysis

One click puts Huakang Biomedical Holdings Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.